Growth factors and cell therapy in myocardial regeneration.
Despite significant advances in myocardial revascularization and reperfusion, coronary artery disease and subsequently myocardial infarction, are the leading cause of morbidity and mortality in the US. Thus one of the main goals in the treatment of myocardial ischemia is the development of effective therapy for angiogenesis. The first evidence is the demonstration of alleviation of myocardial ischemia and increased number of collateral blood vessels in the early 1990s following intra-coronary administration of basic fibroblast growth factor protein in dog. Multiple animal studies, has confirmed the concept of stimulation of collateral development by pharmacological and molecular means. This includes direct delivery of growth factors into the ischemic target tissues, or of genes that encode for synthesis of growth factors by target tissues. Both cell therapy and gene therapy have proven to be effective to promote neovascularization in various animal models. Cell therapy alone is proven to be beneficial however the combination of cell and gene therapy (growth factors) may enhance therapeutic neovascularization. Thus clinically relevant, combined strategy could be an excellent strategy for treating patients with myocardial infarction.
Maulik
Nilanjana
N
Department of Surgery, Molecular Cardiology and Angiogenesis Laboratory, University of Connecticut Medical Center, 263 Farmington Avenue, Farmington, CT 06030-1110, USA. nmaulik@neuron.uchc.edu
Thirunavukkarasu
Mahesh
M
D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism* / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D012038:Regeneration / Q000187:drug effects
D036341:Intercellular Signaling Peptides and Proteins